Joshua E. Rodden

Array ( [id] => 17627605 [patent_doc_number] => 20220162620 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => Applications of Streptococcus-derived Cas9 nucleases on minimal Adenine-rich PAM targets [patent_app_type] => utility [patent_app_number] => 17/053713 [patent_app_country] => US [patent_app_date] => 2019-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8371 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17053713 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19969893 [patent_doc_number] => 12338486 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-24 [patent_title] => Single-stranded break detection in double-stranded DNA [patent_app_type] => utility [patent_app_number] => 17/048227 [patent_app_country] => US [patent_app_date] => 2019-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 35 [patent_no_of_words] => 17089 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 293 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17048227 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18102626 [patent_doc_number] => 11542505 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2023-01-03 [patent_title] => Substituted RIG-I agonists: compositions and methods thereof [patent_app_type] => utility [patent_app_number] => 17/047271 [patent_app_country] => US [patent_app_date] => 2019-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35598 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17047271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15035523 [patent_doc_number] => 20190328766 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => COMPOSITIONS AND METHODS FOR SUPPRESSING MSUT2 [patent_app_type] => utility [patent_app_number] => 16/383178 [patent_app_country] => US [patent_app_date] => 2019-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27745 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16383178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15361031 [patent_doc_number] => 20200016280 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => Compositions For Enhancing Transport Of Molecules Into Cells [patent_app_type] => utility [patent_app_number] => 16/379046 [patent_app_country] => US [patent_app_date] => 2019-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18606 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16379046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14994499 [patent_doc_number] => 20190316207 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => MIR-320E AND COLORECTAL CANCER [patent_app_type] => utility [patent_app_number] => 16/372747 [patent_app_country] => US [patent_app_date] => 2019-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17195 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16372747 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19209300 [patent_doc_number] => 11998331 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-04 [patent_title] => Use of micro-ribonucleic acid (miRNA) to diagnose transplant rejection and tolerance of immunosuppression therapy [patent_app_type] => utility [patent_app_number] => 16/365194 [patent_app_country] => US [patent_app_date] => 2019-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 15579 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16365194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14502017 [patent_doc_number] => 20190194663 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-27 [patent_title] => MICRORNA-198 AS A TUMOR SUPPRESSOR IN OVARIAN CANCER [patent_app_type] => utility [patent_app_number] => 16/299986 [patent_app_country] => US [patent_app_date] => 2019-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28150 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16299986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15850547 [patent_doc_number] => 10640539 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-05 [patent_title] => Recombinant protein-based method for the delivery of silencer RNA to target the brain [patent_app_type] => utility [patent_app_number] => 16/278319 [patent_app_country] => US [patent_app_date] => 2019-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 11 [patent_no_of_words] => 4348 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16278319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17089740 [patent_doc_number] => 11117917 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-14 [patent_title] => Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides [patent_app_type] => utility [patent_app_number] => 16/268262 [patent_app_country] => US [patent_app_date] => 2019-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 200 [patent_figures_cnt] => 200 [patent_no_of_words] => 30222 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16268262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14897567 [patent_doc_number] => 20190292549 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => POLY(ETHYLENE GLYCOL) BRUSHES FOR EFFICIENT RNA DELIVERY [patent_app_type] => utility [patent_app_number] => 16/253547 [patent_app_country] => US [patent_app_date] => 2019-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13567 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16253547 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14774959 [patent_doc_number] => 20190262377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS [patent_app_type] => utility [patent_app_number] => 16/246157 [patent_app_country] => US [patent_app_date] => 2019-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37772 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16246157 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15268025 [patent_doc_number] => 20190382746 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => Artificial Ribosomes for Fully Programmable Synthesis of Nonribosomal Peptides [patent_app_type] => utility [patent_app_number] => 16/245984 [patent_app_country] => US [patent_app_date] => 2019-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10331 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16245984 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16627498 [patent_doc_number] => 20210046151 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING PULMONARY METASTASIS OF CANCER INCLUDING CHI3L1 INHIBITOR AS ACTIVE INGREDIENT [patent_app_type] => utility [patent_app_number] => 16/957249 [patent_app_country] => US [patent_app_date] => 2018-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15377 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16957249 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14625205 [patent_doc_number] => 20190225970 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-25 [patent_title] => MODULATORS OF GROWTH HORMONE RECEPTOR [patent_app_type] => utility [patent_app_number] => 16/234409 [patent_app_country] => US [patent_app_date] => 2018-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58476 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16234409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16539236 [patent_doc_number] => 20200405649 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => DNA ORIGAMI NANOPARTICLE DELIVERY OF PROGRAMMED CHROMOSOME BREAKAGE MACHINERY [patent_app_type] => utility [patent_app_number] => 16/956827 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3125 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16956827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16399124 [patent_doc_number] => 20200339982 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE [patent_app_type] => utility [patent_app_number] => 15/733307 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44751 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15733307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16429738 [patent_doc_number] => 10829812 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-11-10 [patent_title] => Amplification of oligonucleotides containing non-standard nucleotides [patent_app_type] => utility [patent_app_number] => 16/216266 [patent_app_country] => US [patent_app_date] => 2018-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 8232 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 249 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16216266 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14099117 [patent_doc_number] => 20190091234 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => GAMMA-SECRETASE INHIBITION REDUCE APOC3 LEVELS AND PLASMA TRIGLYCERIDES [patent_app_type] => utility [patent_app_number] => 16/212174 [patent_app_country] => US [patent_app_date] => 2018-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11223 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16212174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16635450 [patent_doc_number] => 10913946 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-09 [patent_title] => RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy [patent_app_type] => utility [patent_app_number] => 16/201951 [patent_app_country] => US [patent_app_date] => 2018-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 18 [patent_no_of_words] => 50429 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16201951 [rel_patent_id] =>[rel_patent_doc_number] =>)